Reaction
Gastrointestinal Scarring reporting signals
As of the last recalculation, Gastrointestinal Scarring appears in 693 FAERS reports alongside 7 co-occurring drug terms. The strongest observed disproportionality signal is RISANKIZUMAB-RZAA (PRR 48.4).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Risankizumab-Rzaa | 111 | 48.4 | 48.4 |
| Vedolizumab | 98 | 39.6 | 39.7 |
| Meperidine Hydrochloride | 8 | 26.4 | 26.4 |
| Iron Sucrose | 8 | 25.5 | 25.5 |
| Upadacitinib | 47 | 18.5 | 18.5 |
| Teduglutide | 8 | 18.0 | 18.0 |
| Polatuzumab Vedotin | 3 | 9.3 | 9.3 |